PUMA BIOTECHNOLOGY INC
PBYINASDAQTrading Snapshot
- Day Range
- $9.70 – $9.95
- 52-Week Range
- $4.58 – $9.98
- Volume
- $6.10B
- Avg Volume
- $6.92B
- Shares Outstanding
- 50.9M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $228M
- Last Q Revenue
- $57M
- P/E Ratio
- 18.3
- P/S Ratio
- 2.2x
- EPS (TTM)
- $0.52
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.3%
Why Investors Own PBYI
- ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PUMA BIOTECHNOLOGY INC
PBYI
StockOtter · stockotter.spaceAbout PUMA BIOTECHNOLOGY INC
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
PUMA BIOTECHNOLOGY INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift PBYI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
PUMA BIOTECHNOLOGY INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.